Immunic, Inc.
General ticker "IMUX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $202.9M (TTM average)
Immunic, Inc. follows the US Stock Market performance with the rate: 50.4%.
Estimated limits based on current volatility of 3.5%: low 14.56$, high 15.62$
Factors to consider:
- Total employees count: 77 (+16.7%) as of 2023
- Top business risk factors: Inability to achieve profitability, Operational and conduct risks, Clinical trial failure, Regulatory and compliance, Capital shortage
- Current price 49.8% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.00$, 9.51$]
- 2026-12-31 to 2027-12-31 estimated range: [2.06$, 6.85$]
Financial Metrics affecting the IMUX estimates:
- Positive: with PPE of -0.8 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -99.25 <= 0.28
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of -0.19 > -0.64
- Positive: Shareholder equity ratio, % of -27.74 <= 18.97
Short-term IMUX quotes
Long-term IMUX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $99.22MM | $98.05MM | $103.23MM |
| Operating Income | $-99.22MM | $-98.05MM | $-103.23MM |
| Non-Operating Income | $5.61MM | $-2.46MM | $6.06MM |
| R&D Expense | $83.22MM | $80.05MM | $81.98MM |
| Income(Loss) | $-93.61MM | $-100.51MM | $-97.17MM |
| Net Income(Loss)* | $-93.61MM | $-100.51MM | $-97.17MM |
| Stockholders Equity | $28.93MM | $18.43MM | $-6.67MM |
| Assets | $54.30MM | $40.87MM | $24.05MM |
| Operating Cash Flow | $-70.83MM | $-84.77MM | $-85.81MM |
| Capital expenditure | $0.33MM | $0.26MM | $0.16MM |
| Investing Cash Flow | $9.46MM | $-0.26MM | $-0.16MM |
| Financing Cash Flow | $1.03MM | $74.54MM | $65.58MM |
| Earnings Per Share** | $-21.12 | $-10.03 | $-6.24 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.